Background: Complex post-traumatic stress disorder (C-PTSD) is a trauma-related condition characterized by pervasive disturbances in affect regulation, self-concept, and interpersonal functioning that extend beyond the symptom profile of post-traumatic stress disorder (PTSD). While neurobiological studies have implicated limbic, salience, and prefrontal systems in C-PTSD, mechanistic accounts...
There is growing interest in novel approaches to treating posttraumatic stress disorder (PTSD), including the use of psychedelic substances combined with psychotherapy, often referred to as psychedelic-assisted therapy, to better meet the needs of patients who do not prefer or respond to traditional evidence-based treatments. Among these treatments, 3,4-methylenedioxymethamphetamine...
Posttraumatic stress disorder (PTSD) is a chronic and disabling condition and identifying beneficial therapies is timely and important. We aimed to estimate the efficacy of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) compared with control on clinical and functional outcomes in PTSD. A PRISMA-compliant search (PROSPEROCRD42022353261) up to August 14, 2025, covered nine databases...
MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD. Studies suggest treatment with these agents under supervision may lead to improvements in PTSD symptoms, with the medications being generally well tolerated. However, caution should be used when interpreting study results due to limitations such as treatment expectancy effect and the potential for...
S elective S erotonin R euptake I nhibitors (SSRIs) and two psychedelics, Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), and MDMA (3,4-Methylenedioxymethamphetamine) act on serotonergic-related neural circuits and function as serotonin modulators. All three molecules are either currently used or proposed as novel therapeutic modalities to treat P ost- T raumatic S tress D isorder (PTSD)....
MDMA-assisted psychotherapy has emerged as a promising treatment for post-traumatic stress disorder (PTSD), particularly in individuals unresponsive to conventional interventions such as SSRIs and trauma-focused cognitive behavioral therapy. As recent clinical trials report durable symptom remission, ongoing debate surrounds the mechanisms underlying its therapeutic effects. This review...
Recent research has highlighted the potential of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for the treatment of post-traumatic stress disorder and other trauma-related psychiatric conditions. However, less is known about the effects of MDMA use on psychological well-being in populations with trauma histories outside of clinical contexts. In the present study, we assessed...
Australia recently became the first country to reschedule methylenedioxymethamphetamine (MDMA) to permit authorized prescribing for post-traumatic stress disorder (PTSD) outside of clinical trials. This study explored the direct experience of Australian clinicians, researchers, and patients regarding the use of MDMA-assisted psychotherapy (MDMA-AP) for PTSD to inform guideline development....
3,4‐Methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy (MDMA‐AP) has shown promise in treating post‐traumatic stress disorder (PTSD), particularly in treatment‐resistant cases. However, little is known about its potential to precipitate adverse psychiatric outcomes. We present the case of a 31‐year‐old woman with nondistressing childhood compulsions, chronic PTSD, and complex medical...
Patients with eating disorders (EDs), particularly anorexia nervosa (AN), experience a complex psychiatric condition often characterized by extreme food restriction, intense fear of weight gain, elevated levels of emotional dysregulation, body image disturbance, and comorbid trauma. Several of these factors can undermine the therapeutic alliance and reduce engagement with treatment,...